Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2015
Event: Entry into a Material Definitive Agreement regarding the acquisition of HEKA Electronik operations.
Key Financial Metrics and Transaction Details
This filing reports a specific acquisition transaction rather than periodic financial performance metrics (revenue, profit, cash flow, or margins). The filing does not provide a clear value for the company's overall liquidity or debt position outside of this transaction.
- Total Acquisition Cost: Approximately $6 million in cash.
- Target: HEKA Electronik, a privately held biomedical instrumentation and software business.
- Entities Acquired:
- HEKA Electronik Dr. Schulze GmbH (Germany)
- HEKA Electronics Incorporated (Canada)
- HEKA Instruments Incorporated (US)
- Payment Structure:
- HEKA Germany: Approximately €2.2 million in cash.
- HEKA Canada & US: Approximately €2.8 million in cash (paid in Canadian dollars).
Material Changes and Transaction Terms
The primary material change is the expansion of the Company's operations through the acquisition of HEKA Electronik. Key terms include:
- Closing Date: January 8, 2015 (simultaneous with signing of agreements).
- Price Adjustments: Both purchase agreements include customary post-closing adjustments based on closing calculations of financial liabilities, cash, and working capital.
- Non-Competition: Sellers agreed to non-compete provisions for a period of two years following the closing date.
- Acquiring Subsidiaries:
- HEKA Germany acquired by Multi Channel Systems MCS GmbH (wholly owned subsidiary).
- HEKA Canada and US acquired by Ealing Scientific Limited (wholly owned subsidiary).
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the standard representations, warranties, and indemnification provisions customary in share purchase agreements. The transaction is presented as completed.
Important Facts for Investor Verification
- Verify the final purchase price after post-closing adjustments for working capital and liabilities.
- Confirm the impact of the $6 million cash outflow on the Company's current liquidity position.
- Review the press release (Exhibit 99.1) for strategic rationale and integration plans.
- Monitor future filings for the financial performance of the newly acquired HEKA entities.